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Alagille syndrome (AGS) is a complex disorder withmultisystemic involvement, including the liver,heart, kidneys, cerebral vasculature, skeleton, eyes,and face.1 A structural heart defect is one of the
diagnostic criteria for AGS. These vary in severity, with pe-
ripheral pulmonary arterial stenosis being a common problem.
Pulmonary atresia (PA) is a rare presentation in AGS, but we
were impressed by the poor outcome of such infants following
review of our institutional experience over the last 20 years.
The information has particular relevance in this era where
prenatal diagnosis of both AGS and PA can be made.
Clinical Summary
A number of information sources including cardiac, genetic, and
gastroenterology departmental databases and hospital medical
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TABLE 1. Clinical summary, surgical procedures, and outcomes in 5 cases presenting with Alagille syndrome and
pulmonary atresia between 1985 and 2005
Patient
(gender)
Born/status/age
at last follow-up Cardiac lesions Alagille-specific features Genetics/family history
1 (M) 2003/alive/2.5 y PA/VSD/PAH with minor
collaterals
Jaundice, butterfly vertebra,
radioulnar synostosis, mild
facial dysmorphism
JAG1 mutation/mother and
maternal aunt have mutation
and mild cardiac problems,
maternal cousin has CHD
2 (M) 2002/dead/2.5 y PA/IVS/PAH with
MAPCAs
Butterfly vertebra, pointed chin,
high forehead, bilateral
Axenfeld-Reiger anomaly
JAG1 mutation/father has heart
murmur, paternal grandfather
has had mitral valve
replacement, no family gene
testing
3 (M) 1995/dead/2.5 y TOF/PAH Decreased bile ducts, prominent
forehead, pointed chin
No testing/father has TOF, 2
siblings have pulmonary
valve stenosis
4 (F) 1987/dead/5.5 y PA/VSD/PAH with
MAPCAs
Paucity of intrahepatic bile ducts,
frontal bossing, small mandible,
butterfly vertebra, global DD
No testing/no mention of
similar conditions in
immediate or extended family
members
5 (M) 1976/dead/20 y PA/VSD/PAH with
MAPCAs
Thickened portal tracts, butterfly
vertebrae, prominent forehead,
pointed chin
No testing/no mention of
similar conditions in
immediate or extended family
members
PA, pulmonary atresia; VSD, ventricular septal defect; IVS, intact ventricular septum; PAH, pulmonary artery hypoplasia; TOF, tetralogy of Fallot; MAPCAs,
major aortopulmonary collateral arteries; DD, developmental delay; CHD, congenital heart disease; DUA, death under anesthesia; RV, right ventricle.
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records were searched and cross-referenced to identify patients
with AGS and/or PA between 1985 and 2004. We identified 26
patients with AGS and 505 patients with PA, 5 of whom had both
diagnoses. Patients with AGS and only peripheral pulmonary
arterial stenoses were excluded. Our institution serves a population
of more than 6 million people, performs more than 400 cardiac
procedures annually, and has a raw operative mortality of 2%.
Five cases of AGS with PA were identified (see Table 1): 4
with PA and ventricular septal defect (VSD), 1 with PA and intact
ventricular septum. Four of 5 patients (80%) have died as a result
of cardiac disease, and the remaining individual is receiving pal-
liative management.
The most striking feature is the failure of small pulmonary
arteries to grow following systemic-to-pulmonary arterial shunts.
In 3 patients, collateral pulmonary blood flow was deemed suffi-
cient to allow delay in initial surgery for more than 6 months.
Where pulmonary arteries have been considered to be borderline
adequate, establishment of a pulmonary arterial confluence and/or
biventricular repair have not been successful.
Discussion
AGS is an autosomal-dominant disorder caused by mutations or
deletions in the JAG1 gene, located on chromosome 20p11.2-20p12.
The JAG1 gene produces a protein, Jagged1, which is an important
ligand in the NOTCH signaling pathway and plays an important role
in early cell determination.2 The expression of Jagged1 within the
developing embryo of both mice and humans correlates with cardio-
vascular disease in AGS.3 Expression is primarily seen in structures
destined to become part of the right-sided circulatory system, includ-
ing the sixth pharyngeal arch, which gives rise to the pulmonary
artery, as well as in the pulmonary outflow tract. No clear genotype–
phenotype correlations have yet been established to account for the
high degree of variability of both the number and the extent to which
the various organ systems are involved. In a study of monozygotic
twins with an identical splice site mutation in JAG1, 1 twin had PA
and the other had only mild cardiac disease but more severe hepatic
involvement.4 Although it is recognized that mutations or deletions in
JAG1 cause AGS, other factors including environmental triggers,
modifying genetic loci, and epigenetic factors may contribute to the
phenotype of an individual, as is the case in many other forms of
structural heart disease.
Cardiac disease significantly impacts on the life expectancy
of patients with AGS and accounts for 34% of mortality.1 PA
alone, with or without a VSD, is a serious condition; however,
with contemporary surgical techniques, most patients survive
infancy, with an increasing number expected to achieve biven-
tricular repair.l It is not clear why the patients with AGS who
received systemic-to-pulmonary shunts did not show evidence
of pulmonary arterial growth. In the 3 who had generous
collateral flow, initial palliation was deferred, but in the current
TABLE 1. Continued
1st surgery age/
description 2nd surgery age/description
3rd surgery
age/description
4th surgery
age/description Comments
9 d/central
shunt (4 mm)
4 mo/augment central shunt
(5 mm) utilizing
cardiopulmonary bypass
1 y 1 mo/modified
right Blalock shunt
(4 mm)
1 y 10 mo/modified
left Blalock
shunt (5 mm)
Failure of pulmonary arteries to
grow despite augmentation of
pulmonary blood flow
27 d/pulmonary
valve balloon
dilation
3 mo/modified right Blalock
shunt (4 mm)
— — Extremely hypoplastic pulmonary
arteries despite shunt; no
further surgery undertaken
6 mo 19
d/central
shunt (4 mm)
6 mo 20 d/left Blalock shunt
(5 mm)
2 y 3 mo/attempted
biventricular repair
with RV-PA
conduit
— Initial shunt blocked; following
repair, high RV pressures, VSD
patch fenestrated; DUA
9 mo/left
Blalock
shunt (5 mm)
1 y 8 mo/recruitment
MAPCAs and right
Blalock shunt (5 mm)
5 y 7 mo/attempted
establishment of
pulmonary arterial
continuity
— Difficulty establishing satisfactory
pulmonary artery confluence;
attempted bilateral systemic-
pulmonary shunt without RV to
pulmonary artery conduit; DUA
6 y 3 mo/right
Blalock
shunt (5 mm)
14 y 7 mo/recruitment of
MAPCAs, left Blalock
shunt (6 mm)
14 y 8 mo/pericardial
drainage
— Difficulties recruiting MAPCAs,
coagulopathy from liver
disease and aortic
incompetence; further surgery
not offered
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era we would aim to augment pulmonary blood flow as soon as
possible to achieve what pulmonary arterial growth is possible.
Unfortunately, even when this approach was aggressively em-
ployed (case 1), satisfactory pulmonary vascular development
has not been achieved.
Our study expands on a theme identified by McElhinney and
colleagues,2 who noted that patients with a JAG1 mutation and
PA/VSD had a poor outcome, with 6 of 8 patients (75%) not surviving
treatment in infancy. The survival rate in their patient group mirrors
that of our cohort and highlights the severity of the condition. These
results have implications for clinical decision making and manage-
ment of PA in the context of AGS and allow us to calibrate expec-
tations for those requiring surgery.
We acknowledge the contributions of Prof Tim Cartmill, Dr
David Johnson, Dr Graham Nunn, Dr Ian Nicholson, and Dr
Stephen Cooper, who were involved in the clinical management of
these patients.
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Infant arch reconstruction during total system perfusion
Aimee B. Gardner, BS, CCP, and Pirooz Eghtesady, MD, PhD, Cincinnati, Ohio
Currently, neonatal arch reconstruction requires the useof circulatory arrest or, predominantly, regional cere-bral perfusion techniques.1 With regional perfusion,the question remains as to the adequacy of brain per-
fusion.2,3 Recent clinical and experimental evidence suggests that,
with all techniques, systemic perfusion is sacrificed and unwanted
effects of deep hypothermia remain. W i t h t h e u s e o f t h e INVOS
cerebral oximeter (Somanetics, Troy, Mich), changes in the
regional cerebral oxygen saturation are now noninvasively and
continuously monitored, allowing for the comparison of differ-
ent techniques. We present a case of successful aortic arch
reconstruction in an infant using a novel technique that allows
total cerebral as well as systemic perfusion during arch recon-
struction.
Clinical Summary
A 6-month-old infant with Shone’s anomaly, who had undergone
a previous repair of coarctation of aorta and total anomalous
pulmonary venous return, developed a new arch that narrowed
between the innominate artery and left carotid takeoff. Because of
worsening left ventricular hypertrophy, increased left ventricular
end diastolic pressure, and a mild increase in right-sided pressures,
reintervention was recommended.
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doi:10.1016/j.jtcvs.2006.10.072 Figure 1. Positioning of Pruitt–Inahara shunt for aortic arch re-
pair. CPB, cardiopulmonary bypass.
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